The FDA last week approved...

...Octapharma's Wilate for the treatment of Hemophilia A, both for routine management of the disease and as needed to control a single bleeding episode. Wilate was previously only approved for the treatment of Von Willebrand disease. In the pharmacy benefit, Wilate holds preferred formulary status for 12% of covered lives. In the medical benefit, Wilate is covered without restrictions for 33% of lives.

SOURCE: MMIT Analytics, as of 10/14/19